About You

By reducing the time it takes for the body to utilize the ingredients - users experience quicker results in muscle recovery, strength and size. This advanced delivery system maximizes the efficiency - promoting faster anabolic activity and muscle growth. Another key ingredient in ANABOL HARDCORE – is 6-Keto-Diosgenin Decanoate - which works to promote long-lasting anabolic activity, helping to build and preserve lean muscle mass.
The side effects of treatment were transient drowsiness and weight gain. Ten of the 15 women had menstrual bleeding while receiving Anabol, seven had decreased galactorrhea, and two had cessation of galactorrhea. You should stop taking Anabol once your symptoms have eased.
Extraction of hormones from urines began in China around 100 BCE.citation needed Medical use of testicle extract began in the late 19th century while its effects on strength were still being studied. Use of cow urine for treatment of ascites, heart failure, renal failure and vitiligo has been elaborately described in Sushruta Samhita, suggesting that ancient Indians had some understanding of steroidal properties of cow urine around 6th century BCE. The most commonly employed human physiological specimen for detecting AAS usage is urine, although both blood and hair have been investigated for this purpose. DHT, via its metabolite 3α-androstanediol (produced by 3α-hydroxysteroid dehydrogenase (3α-HSD)), is a neurosteroid that acts via positive allosteric modulation of the GABAA receptor. Aside from prohormones and testosterone undecanoate, almost all orally active AAS are 17α-alkylated. In contrast to most other AAS, 17α-alkylated testosterone derivatives show resistance to metabolism due to steric hindrance and are orally active, though they may be esterified and administered via intramuscular injection as well.
Aside from 5α-reductase, aromatase may inactivate testosterone signaling in skeletal muscle and adipose tissue, so AAS that lack aromatase affinity, in addition to being free of the potential side effect of gynecomastia, might be expected to have a higher myotrophic–androgenic ratio in comparison. As so-called "androgenic" tissues such as skin/hair follicles and male reproductive tissues are very high in 5α-reductase expression, while skeletal muscle is virtually devoid of 5α-reductase, this may primarily explain the high myotrophic–androgenic ratio and dissociation seen with nandrolone, as well as with various other AAS. According to the intracellular metabolism explanation, the androgenic-to-anabolic ratio of a given AR agonist is related to its capacity to be transformed by the aforementioned enzymes in conjunction with the AR activity of any resulting products.
Notably, the ventral prostate of the rat became the model organ for androgenic activity in the renowned Hershberger androgen bioassay, which was developed in 1953 (82). However, whereas testosterone is converted into the more potent androgen DHT by 5α-reductase (21), the conversion of nandrolone into DHN yields an androgen with significantly lower binding affinity for the AR (77, 78). Similarly, it was later described that males born with 5α-reductase (the enzyme responsible for conversion of testosterone into DHT) deficiency never developed male-pattern hair loss either (73). In the 1940s, James Hamilton described how male-pattern baldness did not develop in castrated men unless they were administered testosterone (72).
These women have little or no sebum production, incidence of acne, or body hair growth (including in the pubic and axillary areas). However, women with complete androgen insensitivity syndrome (CAIS), who have a 46,XY ("male") genotype and testes but a defect in the AR such that it is non-functional, are a challenge to this notion. Whether this is involved in the differences in the ratios of anabolic-to-myotrophic effect of different AAS is unknown however. In addition, at the time of puberty, such males develop normal musculature, voice deepening, and libido, but have reduced facial hair, a female pattern of body hair (i.e., largely restricted to the pubic triangle and underarms), no incidence of male pattern hair loss, and no prostate enlargement or incidence of prostate cancer. Dissociation between the ratios of these two types of effects relative to the ratio observed with testosterone is observed in rat bioassays with various AAS. Endogenous/natural AAS like testosterone and DHT and synthetic AAS mediate their effects by binding to and activating the AR.
Nevertheless, it should be appreciated that the accuracy of the equation is predicated on the assumption that serum creatinine levels accurately reflect the GFR – which is doubtful in this particular population. Serum creatinine levels are commonly used to estimate the glomerular filtration rate (eGFR) using formulas such as the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (157). The use of HDL-cholesterol boosting supplements, such as niacin, could also lead to underestimating risk when using algorithms based on HDL-cholesterol. Echocardiographic proof of such changes might therefore aid in ‘grey zone’ risk estimation situations. It seems appropriate to manage dyslipidemia in (long-term) AAS users according to current guidelines (151) just as in any other patient. This might help explain the results of a population-based cohort study in which men that tested positive for AAS had twice the cardiovascular morbidity and mortality rate as those who tested negative (149).
Among AAS users there is the belief that AAS might cause gynecomastia through alternative pathways, such as increased progestin action at the mammary glands or increased prolactin levels. In contrast, the prevalence of gynecomastia increased from 7% at baseline to 19% at the end of an AAS cycle in the HAARLEM study (39). SERMs are capable of negating the negative feedback imposed by estrogens and are therefore commonly used by AAS users to supposedly aid in recovery of testosterone production after an AAS cycle (‘post-cycle therapy’). Bioactivation of the prohormone into the potent anabolic steroid 17β-hydroxy-5α-androst-1-en-3-one (1-testosterone) results from oxidation at carbon 3 of the A-ring and reduction at carbon 17 of the D-ring of the steroid nucleus (156). Regardless, the benefit of therapeutically decreased Lp(a) on CVD risk remains unclear (142) and might only be potentially beneficial for those with elevated Lp(a) levels that correlate with increased CVD risk, which encompasses 15–20% of the population (143). However, administration of a low dosage (6 mg daily) of stanozolol (a 17α-alkylated anabolic steroid) for 2 weeks reduced HDL-cholesterol levels by 20% in 2 HL-deficient brothers (130).
Androgens were discovered in the 1930s and were characterized as having effects described as androgenic (i.e., virilizing) and anabolic (e.g., myotrophic, renotrophic). They are completely insensitive to the AR-mediated effects of androgens like testosterone, and show a perfectly female phenotype despite having testosterone levels in the high end of the normal male range. It has been proposed that differential signaling through mARs may be involved in the dissociation of the anabolic and androgenic effects of AAS. The intracellular metabolism theory explains how and why remarkable dissociation between anabolic and androgenic effects might occur despite the fact that these effects are mediated through the same signaling receptor, and why this dissociation is invariably incomplete.

Profile Info